clinical trial · NCT05229900
A Study of SGN-ALPV in Advanced Solid Tumors
Ovarian NeoplasmsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungStomach NeoplasmsGastroesophageal Junction CarcinomaUterine Cervical NeoplasmsTesticular NeoplasmsSGN-ALPV
brief summary
This study will test the safety of a drug called SGN-ALPV in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have three parts. Parts A and B of the study will find out how much SGN-ALPV should be given to participants. Part C will use the dose and schedule found in Parts A and B to find out how safe SGN-ALPV is and if it works to treat solid tumor cancers.
started
Apr 21, 2022
primary completion
Dec 13, 2023
completion
Dec 13, 2023
last updated
Feb 10, 2025
official title
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol